Pharmaceutical Technology

FEBRUARY 19, 2023

STRO-002 is under clinical development by Sutro Biopharma and currently in Phase I for Refractory Acute Myeloid Leukemia. The company works in partnership with other pharmaceutical and biotechnology companies for pre-clinical development of novel antibody drug conjugates.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

The Pharma Data

DECEMBER 13, 2020

2] Pre-clinical studies have shown that these differentiated properties of HMBD-001 lead to robust and sustained tumor growth inhibition in multiple HER3 cancer models, including those with NRG1-fusions. Our highly experienced teams in Singapore and the US span antibody discovery, pharmacology, production and clinical development.

Clinical Development 52

Clinical Development Medicine Development Antibody 52

Pharmaceutical Technology

OCTOBER 3, 2022

Indonesia has granted Emergency Use Authorization (EUA) for the patent-free Covid-19 vaccine, IndoVac, developed by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine, US. PT Bio Farma will manufacture 20 million doses of the vaccine this year.

Vaccination 130

Vaccination Vaccine Development Production 130

Pharmaceutical Technology

FEBRUARY 24, 2023

ACE-1334 is under clinical development by Merck and currently in Phase I for Lung Disease. ACE-1334 overview ACE-1334 is under development for the treatment of pulmonary disease with fibrotic component and systemic sclerosis and its associated interstitial lung disease. It is developed based on protein engineering platform.

Production 100

Production Vaccination Vaccine Engineer 100

Pharmaceutical Technology

AUGUST 17, 2022

oRNA molecules have been demonstrated to possess increased stability in vivo compared to linear mRNA and can potentially create more quantities of therapeutic proteins within the body. . By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. The therapeutic candidate targets immune checkpoint, programmed cell death protein 1 (PD1). It is developed based on sympress platform technology. It is administered as an intravenous infusion.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

pharmaphorum

MARCH 23, 2022

Merck & Co’s chief medical officer and head of clinical development Dr Roy Baynes has announced his retirement from the company to take up a new role alongside his former colleague Roger Perlmutter at biotech Eikon Therapeutics. billion last year.

Clinical Development 98

Clinical Development FDA Approval Vaccination Vaccine 98

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

pharmaphorum

APRIL 23, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . For example, adding a small-molecule might stabilise the medicine, allowing levels of the target protein to increase.

Gene Editing 52

Gene Editing Genetics Drugs Gene 52

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Drugs 59

Drugs Licensing Licensing Protein 59

The Pharma Data

APRIL 15, 2022

A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. The findings were published yesterday (April 12) in the journal Science Translational Medicine.

Antibody 52

Antibody Protein Engineer Manufacturing 52

pharmaphorum

MAY 13, 2021

These allow the body to produce a correct version of the misfolded dystrophin protein that is the root cause of DMD. But gene therapies go one step further by inserting the dystrophin gene into the patient’s muscle tissue, in order to produce a working version of the protein that is essential for building muscles.

Gene Therapy 93

Gene Therapy Gene Trials Protein 93

pharmaphorum

SEPTEMBER 14, 2020

AstraZeneca has resumed UK trials for its coronavirus vaccine, after the country’s medicines regulator gave the all-clear following a safety scare. A UK safety committee has concluded its investigations and recommended to the country’s Medicines and Healthcare products Regulatory Agency (MHRA) that trials are safe to resume.

Vaccination 87

Vaccination Vaccine Trials Protein 87

pharmaphorum

JULY 5, 2022

Cell therapy specialist Mogrify has struck a deal with Japanese drugmaker Astellas to look at ways to deploy regenerative medicine to treat hearing loss caused by factors such as chronic exposure to loud noises. An estimated 1.57 The post Astellas teams up with UK biotech Mogrify on hearing loss project appeared first on.

In-Vivo 105

In-Vivo Bioinformatics Genetics Licensing 105

XTalks

MAY 9, 2024

As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

pharmaphorum

DECEMBER 21, 2021

The Kadmon deal also included an immuno-oncology candidate – anti-PD-L1/IL-15 fusion protein KD033 – which is in early clinical development. Earlier in the year Sanofi also bought Kymab and its atopic dermatitis drug KY1005 for $1.1 billion upfront.

Licensing 124

Licensing Licensing Protein Clinical Development 124

pharmaphorum

NOVEMBER 12, 2020

Regulators sitting on the European Medicines Agency’s CHMP scientific committee have already begun a rolling review of the vaccine, which will accelerate the process as they will be able to study trial results as they are made available. billion doses in 2021.

Vaccination 105

Vaccination Vaccine Manufacturing Regulation 105

Drug Discovery World

AUGUST 28, 2023

DS: Samsara’s autophagy inducing candidate SAM001 will be the first agent of its class to enter clinical trials. It is the method for removing unwanted debris, e.g., old proteins, and breaking them down so their constituent parts can be used again. What is autophagy? How does SAM001 work? PH: Autophagy is the cell’s recycling process.

Genetics 52

Genetics Protein Genetic Disease Clinical Trials 52

XTalks

MARCH 28, 2024

Progressive muscle weakness in the disease is caused by genetic mutations in the dystrophin gene that lead to a lack of functional dystrophin protein. McDonald, MD, professor at the Department of Pediatrics and Physical Medicine Rehabilitation at the University of California Davis Health and investigator for the EPIDYS trial.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

The Pharma Data

MAY 31, 2022

More than 5,000 patients have now been treated worldwide with Evrysdi in clinical trials, compassionate use or real-world settings. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Food and Drug Administration in 2017. Food and Drug Administration in 2017.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

The Pharma Data

DECEMBER 10, 2020

executive vice president of research and development. “We We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”. For additional information, please visit www.lexpharma.com. Safe Harbor Statement.

Containment 52

Containment Clinical Development Development Protein 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

XTalks

JULY 17, 2023

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab. Furthermore, atezolizumab is in Phase II clinical development by F.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

pharmaphorum

SEPTEMBER 1, 2020

The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit.

RNA 52

RNA Drugs Protein Clinical Development 52

The Pharma Data

DECEMBER 31, 2020

where he led global clinical development programs including clinical strategy, clinical development, and regulatory affairs. Prior to Taiho, he held the positions of senior vice president of Clinical Oncology and CMO at Geron Corporation. and CMO for Taiho Oncology, Inc. Source link.

Gene Therapy 52

Gene Therapy Engineer Gene Research Analyst 52

The Pharma Data

MARCH 27, 2023

Executive Vice President and Chief Clinical Development Officer for Ionis, said: “These latest results from our NEURO-TTRansform study represent an important step towards delivering a potential new therapy for ATTRv-PN patients living with this debilitating and fatal disease. Sami Khella, M.D., Eugene Schneider, M.D.,

Trials 40

Trials Protein Medicine Development 40

XTalks

FEBRUARY 24, 2023

Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that works by targeting the protein CD20 on the surface of B cells and CD3 on the surface of T cells. As a chemo-free, fixed-duration medicine, Lunsumio allows people with relapsed or refractory FL to have time off therapy instead of staying on treatment until their cancer progresses.

FDA Approval 52

FDA Approval Drugs Antibody Medicine 52

Pfizer

AUGUST 3, 2022

Based on these results, the Phase 3 trial and further development of PF-07265803 will be discontinued. mitogen activated protein kinase pathway, which demonstrated improvement in functional capacity (6-minute walk test; 6MWT) in a 48-week, open-label, Phase 2 study among patients with symptomatic LMNA-related DCM. COVID-19, Vaccines.

Development 101

Development Vaccination Vaccine Production 101

XTalks

SEPTEMBER 21, 2023

XTALKS WEBINAR: Clinical Trial Risk Identification, Management and Reporting from Clinical Development to Marketing Live and On-Demand: Friday, October 27, 2023, at 10am EDT (4pm CEST/EU-Central) Register for this free webinar to learn how to successfully develop and maintain the safety profile of medicinal products.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

pharmaphorum

OCTOBER 13, 2022

million in future payments tied to preclinical, clinical development, and commercial achievements. Vividion will contribute its ability to find previously unknown functional binding pockets on molecules like proteins or transcription factors that can be targeted with drug compounds. Bayer bought Vividion for $1.5

Gene Therapy 64

Gene Therapy Genome Genomics Drugs 64

Pharmaceutical Technology

JULY 18, 2022

There are currently no approved therapies for the treatment of bronchiectasis; although some off-label medicines do exist, they only alleviate symptoms and manage frequent infections. There have recently, however, been some notable developments towards improving the care of bronchiectasis patients.

Marketing 147

Marketing Trials Development Protein 147

pharmaphorum

SEPTEMBER 18, 2020

Chiesi meanwhile is paying $25 million to kick off a project focusing on the discovery and development of mRNA-based drugs for the rare disease pulmonary arterial hypertension (PAH), with up to $400 million in follow-up payments in the offing.

Gene Editing 101

Gene Editing Gene Vaccination Vaccine 101

The Pharma Data

NOVEMBER 5, 2021

Cases in cohort A (16 with C3G, but who haven’t had a order transplant ( native C3G)) showed a significant 45 reduction in proteinuria (protein in urine) compared to birth, as measured by 24-hour urinary protein to creatine rate (UPCR 24h; P = 0.0003) 1. “

Protein 52

Protein Development Drugs Medicine 52

The Pharma Data

JUNE 7, 2023

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

The Pharma Data

DECEMBER 21, 2020

Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. However, there has so far been limited progress in applying this exciting approach to membrane-associated proteins such as GPCRs.

Drugs 40

Drugs Protein Development Production 40

Drug Discovery World

AUGUST 12, 2022

VLA15 is the only Lyme disease vaccine candidate currently in clinical development. It works by targeting the outer surface protein A (OspA) of the bacteria that cause Lyme disease. Participants will receive three doses of VLA15 or a saline placebo, followed by a booster dose. . Official comments .

Vaccination 52

Vaccination Vaccine Trials Bacteria 52

pharmaphorum

NOVEMBER 9, 2022

for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52